Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.
Hand cleanising gel
With Silver Nano Technology
Nasal spray for rhino-sinusitis.
Dinatri uridin monophosphat 3mg
Dinatri cytidin monophosphat 5mg
Esomeprazole .... 40mg
Treatment of gastroesophageal reflux disease (GERD)
For oral use. Take molnupiravir with or without food. The capsules should be swallowed whole with a sufficient amount of fluid (e.g. a glass of water). The capsules should be not be opened, crushed or chewed.
The recommended dose of molnupiravir is 800 mg (two 400 mg capsules) taken orally every 12 hours for 5 days.
Nervous sytem disorders:
It is a valuable thing that molnupiravir has few interactions with other drugs and it does not negatively affect the treatment of other diseases. Therefore, a COVID-19 patient who is hospitalized for another medical condition (eg, diabetes) and required a COVID-19 treatment (due to elderly or underlying medical conditions), he/she may and should still be prescribed Molnupiravir. Investigators at the University of Medicine and Pharmacy have experience in treating COVID-19 patients who are very old (99 years old) or have many underlying medical conditions. It is important to fully counsel the patient and their family members because in these individuals, severe disease development may not be due to molnupiravir or COVID-19 disease but advanced age or underlying medical conditions affecting the patient's clinical condition.
Cited from “Health
For optimal efficacy, Molnupiravir should be given to elderly COVID-19 patients (over 50 years), patients with underlying medical conditions, or unvaccinated patients. The latest COVID-19 treatment guidelines from the US in January 2022 also indicated the use of Molnupiravir for the above subjects.
Young patients and those without an immune can take Molnupiravir. Young patients without underlying disease and has developed immunity after vaccination or reinfection do not need to be treated with molnupiravir because the benefits do not outweigh the drug-associated potential risks. For the elderly, with underlying medical conditions, even if re-infected, treatment with molnupiravir is required, because this is a group with high risk factors.
(As cited from “Health magazine”: http://www.tcsuckhoe.com/thuoc-khang-virus-molnupiravir-va-nhung-luu-y-khi-su-dung/)
In general, Molupiravir is highly stable and unaffected by light. Therefore, it is enough to just keep the medicine at a stable temperature of about 25°C and not more than 40°C.
(Source: Health Magazine - http://http//www.tcsuckhoe.com/thuoc-khang-virus-molnupiravir-va-nhung-luu-y-khi-su-dung/)
To treat COVID-19 patients who do not need to be hospitalized, in addition to Molunpiravir, according to US FDA guidelines, there are 3 medicines that have been determined to be effective at reducing the risk of severe progression: Paxlovid (oral medicine), monoclonal antibodies and remdesivir (intravenous). However, these drugs are very rare in the Vietnamese market (Remdesivir is possible but in Vietnam only for inpatients because it requires intravenous infusion for 3 days).
Some other antiviral drugs currently available in Vietnam such as favipiravir (Avigan) and umifenovir (Arbinol) may also be effective, but the overall efficacy from studies is lower than that of molnupiravir and has not been included in the US regimen COVID-19 treatment guidelines.
(Source: Health Magazine - http://www.tcsuckhoe.com/thuoc-khang-virus-molnupiravir-va-nhung-luu-y-khi-su-dung/)
Molnupiravir capsules have been clinically tested during the treatment of COVID-19 in the US and India with positive results. Through 3 phases of testing, molnupiravir has succeeded in effectively reducing the viral load with RT-PCR negative results on day 5 reaching 78.3% in the experimental group, compared with 48.4 % in the standard care group.
By the 10th and 14th day of treatment, the remaining patients had RT-PCR negative results. Not only clinical improvement, but the trial also showed an excellent recovery of the patient's health, and confirmed the safety of the drug, no side effects or illnesses were observed during and after duration of the treatments.
In Vietnam, the Ministry of Health also announced positive clinical trial results with 360 patients using this medicine in 2 trial phases. Specifically, 160 phase 1 participants showed positive results for safety, tolerability, and clearance or viral load reduction in patients with mild and moderate COVID-19 after 5 days of treatment. As a result, hospitalization rates and mortality rates have also decreased significantly.
(Source: Health and Lifestyle Magazine - http://https//suckhoedoisong.vn/molnupiravir-thuoc-khang-virus-dau-tien-duoc-chung-minh-tinh-hieu-qua-voi-virus-sar-cov-2%20-169210826160603734.htm)
In case of overdose, medical staffs will closely monitor vital signs (temperature, heart rate, breathing rate, blood pressure, SpO2) and provide supportive treatment if there are problems.
(Sources: Health Magazine - http://http//www.tcsuckhoe.com/thuoc-khang-virus-molnupiravir-va-nhung-luu-y-khi-su-dung/)%20%E2%80%8B
Molnupiravir is prescribed to be taken 12 hours apart from each dose, the effect will last about 16 hours (5 times the half-life of the drug is 3.3 hours). This medicine can be taken at any time, including on an empty stomach or after eating. Some doctors ask patients to drink before eating so that the patient can easily remember when to take the medicine.
(Source: Health Magazine -http://%20http//www.tcsuckhoe.com/thuoc-khang-virus-molnupiravir-va-nhung-luu-y-khi-su-dung/)%20%E2%80%8B
According to the instructions of the prescription, the capsule should not be cut or destroyed to facilitate optimal absorption and to avoid contaminating molnupiravir to others (especially children). However, if there is a COVID-19 patient at risk of severe progression, who needs to be treated with Molnupiravir and cannot swallow the pill, the capsule can be opened or cut to allow the patient to drink the clear powder, but be careful, so the others are not exposed to the medicine unintentionally.
The manufacturer of Molnupiravir Stella 400 mg is Stellapharm Joint Venture Company Limited, established in 2000 (formerly STADA - Vietnam Joint Venture Co., Ltd.), currently the leading pharmaceutical manufacturing enterprise in the field of export pharmaceutical production in Vietnam, especially the European market (SRA).
Stella's products quality has been globally recognized through the assessment and recognition of pharmaceutical authorities around the world such as the European Medicines Agency (EMA), the Japan Pharmaceutical and Medical Devices Agency (PMDA), Taiwan Food and Drug Administration (Taiwan FDA), World Health Organization (WHO) and others. Stella products are now trusted by millions of patients in more than 50 countries worldwide.
(Source: Stella Vietnam - https://www.stelapharm.com/en/about/)
According to international guidelines and data from studies, treatment with molnupiravir does not require and should not be treated with other antivirals, antibiotics or corticosteroids. It is possible to use some medicines to treat symptoms such as antipyretic, cough drops or supplement with vitamins (C, D) and trace elements (such as Zinc). Oriental medicines to treat symptoms can also be used. However, it is necessary to understand the composition of oriental medicines before using them because some of them may have some active ingredients that have an adverse effect on immunity.
(Source: Health Magazine -http://%20http//www.tcsuckhoe.com/thuoc-khang-virus-molnupiravir-va-nhung-luu-y-khi-su-dung/)